3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
9
Colorectal Neoplasms
6
Ovarian Neoplasms
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Uterine Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Sarcoma
1
Lung Neoplasms
1
Liposarcoma
1
Esophageal Squamous Cell Carcinoma
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinosarcoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Lobular
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
3
spartalizumab
2
trametinib
1
tislelizumab
1
palbociclib
1
nazartinib
1
milademetan
1
enzalutamide
1
devimistat
1
dehydroftorafur
1
canakinumab
1
binimetinib
1
bemarituzumab
1
aldesleukin
1
Specimen Handling
1
Pentostatin
1
Midazolam
1
Methods
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Interleukin-2
1
IFL protocol
1
Hydroxychloroquine
1
Gemcitabine
1
Fulvestrant
1
Fluorouracil
1
Early Intervention, Educational
1
Cyclophosphamide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Fulvestrant
×
Gastrointestinal
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled